Palma, Jera M.
HRN: 22-34-55 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/19/2022
CO-AMOXICLAV 625MG (TAB)
12/19/2022
12/26/2022
PO
625mg
Q12
S/P NSVD; UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes